COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM

Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma

Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia

Breast cancer roundup from ASCO 2021

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia